Already in June, the US Medicines Agency raised concerns about the risk of myocarditis linked to the Novavax Covid-19 vaccine.
In a note published this Thursday, July 14, the European Medicines Agency (EMA) notes that the “Nuoxavid” vaccine may cause severe allergic reactions (anaphylaxis): “People who develop a strong allergic reaction after receiving the first dose of Nuvaxovit should not receive a second dose.”Also alerts the system.
The European Institute is a “unusual feeling” Even one “loss of sensitivity” On the skin: “It is difficult to robustly estimate side effect frequencies from reported cases of suspected side effects.”EMA warned.
The warning prompted US officials to warn people with a history of allergic reactions to one of the vaccine’s components. In June, Parisian Only 13,000 French people have been vaccinated with this vaccine.
The Novavax vaccine uses a more traditional technique than the messenger RNA used by Pfizer and Moderna Laboratories to develop their own vaccine. This two-dose vaccine is called a “subunit”: it contains a component of the virus (but not the whole virus) that stimulates immunity. A technique used for vaccines against whooping cough, meningococcal meningitis and hepatitis B.
In June, six cases of myocarditis, an inflammation of the heart muscle, were actually diagnosed in the group of patients who received the vaccine, versus one case in the placebo group, which was later reported to the agency (FDA). Five cases occurred within two weeks of vaccination.